🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

Coronavirus treatment hopes boost European stocks at open

Published 24/08/2020, 08:29
AZN
-
BT
-
STOXX
-
SX8P
-
SX4P
-
SXPP
-

(For a live blog on European stocks, type LIVE/ in an Eikon
news window)
Aug 24 (Reuters) - European stocks bounced from a two-week
low on Monday as signs of progress in developing a COVID-19
treatment offset fears about a resurgence in virus cases across
the continent that could risk stifling an economic recovery.
The pan-European STOXX 600 index .STOXX rose 1.3% by 0713
GMT, mirroring gains for Asian markets after the U.S. health
regulator said on Sunday it authorized the use of blood plasma
from patients who have recovered from COVID-19 as a treatment.
Technology .SX8P , mining .SXPP and chemical .SX4P
companies led the surge in early European trading, gaining more
than 1.5%.
AstraZeneca Plc AZN.L was up 2.1% after the Financial
Times reported the Trump administration was considering
fast-tracking an experimental COVID-19 vaccine being developed
by the company. The gains come after a lacklustre week for European
equities, which were pressured by data pointing to a stalling
business recovery in the euro zone amid a surge in coronavirus
cases.
British telecoms company BT Group BT.L jumped 6.1% to the
top of STOXX 600 after a media report that its board was
preparing to defend it against takeover approaches from rivals
and buyout firms.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.